These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36282294)

  • 1. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
    Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center.
    Zheng C; Xu G; Zhou X; Qiu J; Lan T; Zhang S; Li W
    J Orthop Surg Res; 2024 Aug; 19(1):488. PubMed ID: 39154187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
    J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
    World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
    Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
    Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
    Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
    Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
    Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab combined with en bloc resection and arthrodesis for recurrent grade 3 giant cell tumor of bone in distal radius.
    Li Z; Deng Z; Yang Y; Gao D; Zhang Q; Niu X; Liu W
    J Orthop Surg Res; 2024 Sep; 19(1):607. PubMed ID: 39342379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N; Saito M; Kobayashi E; Morii T; Kikuta K; Watanabe I; Anazawa U; Takeuchi K; Suzuki Y; Susa M; Nishimoto K; Ishii R; Miyazaki N; Mrioka H; Kawai A; Horiuchi K; Nakayama R
    Ann Surg Oncol; 2022 Jun; 29(6):3992-4000. PubMed ID: 35175454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS; Hindiskere S; Doddarangappa S; Pal U
    Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Reoperation for Local Recurrence Following En Bloc Resection for Bone Giant Cell Tumor of the Extremity.
    Tsukamoto S; Mavrogenis AF; Hindiskere S; Honoki K; Kido A; Fujii H; Masunaga T; Tanaka Y; Chinder PS; Donati DM; Errani C
    Curr Oncol; 2022 Sep; 29(9):6383-6399. PubMed ID: 36135072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Giant Cell Tumor of Bone in the Distal Radius and Ulna].
    Mahdal M; Jindra J; Staniczková Zambo I; Pazourek L; Nachtnebl L; Tomáš T
    Acta Chir Orthop Traumatol Cech; 2022; 89(3):188-192. PubMed ID: 35815484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.